Related to Roche’s Avastin Fails to Improve Survival of Advanced Stomach Cancer Patients in Phase III Trial

• FDA Gives Roche’s Avastin the Go-Ahead for Metastatic Renal Carcinoma
  
• Genentech to Buy Lonza-Built Biologics Production Site in Singapore for $290M
  
• OncoMethylome to Carry Out MGMT Assay as Part of Roche’s Phase III Avastin Trial in Glioblastoma
  
• Roche to Plug Over $181M Into Manufacturing Sites to Produce Self-Administration Device for Herceptin
  
• EC Sanctions Roche’s Herceptin for HER2-Positive Metastatic Gastric Cancer
  
• Phase III Trial Suggests Avastin Maintenance Therapy Increases PFS in Advanced Ovarian Cancer
  
• Roche’s Avastin Fails in Late-Stage Hormone-Refractory Prostate Cancer Study
  
• Second Phase III Ovarian Cancer Trial Finds Avastin-Chemotherapy Combo Boosts PFS
  
• FDA Panel Says Nay to Full Approval of Avastin in Her2-Negative Breast Cancer
  
• Roche Claims Phase III Data Supports Use of Avastin in Ovarian Cancer
  
• FDA Clears Herceptin-Chemotherapy Combo for Metastatic Her2+ Gastric Cancer
  
• Avastin Shows Benefits in Phase III Ovarian Cancer Study
  
• EC Approves New Avastin Combination for Breast Cancer
  
• After Panel’s Vote, Fate of Avastin for MBC in U.S. Rests with FDA Commissioner
  
• FDA Revokes Avastin Indication for Treatment of Metastatic Breast Cancer
  
• EC Clears Roche’s Avastin Against Ovarian Cancer
  
• Bayer’s Regorafenib Met Primary PFS Endpoint in Late-Stage GIST Trial
  
• Some Better News for Avastin
  
• EU Clears Avastin as Combo Therapy for Recurrent Ovarian Cancer
  
• Roche’s Avastin Earns First Approval for Aggressive Brain Cancer in Japan